Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.03, Briefing.com reports. The business had revenue of $199.70 million for the quarter, compared to analysts’ expectations of $190.89 million. Apellis Pharmaceuticals had a negative return on equity of 138.32% and a negative net margin of 52.99%. The firm’s quarterly revenue was up 110.2% compared to the same quarter last year. During the same quarter last year, the business earned ($1.02) earnings per share.
Apellis Pharmaceuticals Price Performance
NASDAQ:APLS opened at $36.56 on Monday. The stock has a market capitalization of $4.44 billion, a PE ratio of -10.56 and a beta of 0.88. Apellis Pharmaceuticals has a 1-year low of $19.83 and a 1-year high of $73.80. The firm has a fifty day simple moving average of $39.20 and a 200 day simple moving average of $50.64. The company has a current ratio of 5.08, a quick ratio of 3.02 and a debt-to-equity ratio of 1.73.
Insider Buying and Selling
In other news, Director A. Sinclair Dunlop sold 37,000 shares of the business’s stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $39.24, for a total transaction of $1,451,880.00. Following the transaction, the director now directly owns 136,998 shares in the company, valued at approximately $5,375,801.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director A. Sinclair Dunlop sold 37,000 shares of the firm’s stock in a transaction that occurred on Friday, June 21st. The stock was sold at an average price of $39.24, for a total value of $1,451,880.00. Following the completion of the sale, the director now directly owns 136,998 shares of the company’s stock, valued at $5,375,801.52. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Pascal Deschatelets sold 78,907 shares of the business’s stock in a transaction that occurred on Wednesday, May 8th. The stock was sold at an average price of $42.35, for a total value of $3,341,711.45. Following the transaction, the insider now directly owns 1,115,983 shares in the company, valued at $47,261,880.05. The disclosure for this sale can be found here. 6.80% of the stock is owned by corporate insiders.
Analyst Upgrades and Downgrades
View Our Latest Analysis on APLS
Apellis Pharmaceuticals Company Profile
Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).
Featured Stories
- Five stocks we like better than Apellis Pharmaceuticals
- Using the MarketBeat Dividend Yield Calculator
- Market Crash? No Problem for DoorDash Stock’s Impressive Earnings
- ETF Screener: Uses and Step-by-Step Guide
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.